From the Research
Amaryl (glimepiride) 2 mg is approximately equivalent in effect to Diamicron MR 30 mg (gliclazide modified release). When switching between these sulfonylureas, this is a reasonable starting point for dose conversion, though individual patient response may vary 1. Glimepiride is typically dosed once daily, starting at 1-2 mg and can be titrated up to a maximum of 8 mg daily if needed, while Diamicron MR 30 mg is also given once daily with a maximum dose of 120 mg. Both medications work by stimulating insulin release from pancreatic beta cells, but they have slightly different pharmacokinetic profiles. Glimepiride has a longer duration of action (24 hours) compared to standard gliclazide, though the MR formulation of Diamicron extends its effect throughout the day. Some key points to consider when using these medications include:
- The effective dosage range of glimepiride is 1 to 8 mg/day, with little difference in efficacy between dosages of 4 and 8 mg/day 2
- Glimepiride has been shown to have a lower risk of hypoglycemia and less weight gain compared to other sulfonylureas 2
- Diamicron MR has been shown to be effective and well-tolerated in type 2 diabetes, with a low incidence of hypoglycemia 1 When switching between these medications, blood glucose should be monitored closely as individual responses vary, and dose adjustments may be necessary based on glycemic control. Hypoglycemia is a potential side effect of both medications, particularly in elderly patients or those with renal impairment, so caution is advised when initiating therapy or changing between sulfonylureas 3.